Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy

Authors

Sunita Keshari, University of Texas MD Anderson Cancer Center
Martina Molgora, Washington University School of Medicine in St. Louis
Marco Colonna, Washington University School of Medicine in St. Louis
et al.

Journal

Cell Reports

Publication Date

11-26-2024

Volume

43

Issue

11

First Page

114875

Document Type

Open Access Publication

DOI

10.1016/j.celrep.2024.114875

Rights and Permissions

Keshari S, Shavkunov AS, Miao Q, Saha A, Minowa T, Molgora M, Williams CD, Chaib M, Highsmith AM, Pineda JE, Alekseev S, Alspach E, Hu KH, Colonna M, Pauken KE, Chen K, Gubin MM. Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy. Cell Rep. 2024 Nov 26;43(11):114875. doi: 10.1016/j.celrep.2024.114875. Copyright 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Recommended Citation

Keshari, Sunita; Molgora, Martina; Colonna, Marco; and et al., "Comparing neoantigen cancer vaccines and immune checkpoint therapy unveils an effective vaccine and anti-TREM2 macrophage-targeting dual therapy." Cell Reports. 43, 11. 114875 (2024).
https://digitalcommons.wustl.edu/oa_4/5108

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.